Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
New Weapons to Fight a New Enemy: A Systematic Review of Drug Combinations Against the Drug-Resistant Fungus Candida Auris Publisher Pubmed



Aghaei Gharehbolagh S1 ; Izadi A1 ; Talebi M2 ; Sadeghi F3 ; Zarrinnia A4 ; Zarei F4 ; Darmiani K4 ; Borman AM5, 6 ; Mahmoudi S3
Authors

Source: Mycoses Published:2021


Abstract

Candida auris is an emerging and drug-resistant pathogen. Drug combination is a promising approach against such pathogens. This study was conducted to provide an overview of all the studied drug combinations against C. auris. Relevant articles reporting results of any drug/non-drug combinations against C. auris were found by a systematic search in PubMed, Scopus and Web of Science (ISI), and in Google Scholar up to 1 October 2020. From 187 articles retrieved in the primary search, 23 met the inclusion criteria. In total, 124 different combinations including antifungal with antifungal (45), antifungal with other antimicrobials (11), antifungal with non-antimicrobials (32), antifungal with natural compounds (25) and between natural compounds (11) have been reported. Complete or partial synergistic effects have been reported for 3 out of 45 (6.67%) combinations of two antifungal agents, 8 out of 11 (72.73%) combinations involving antifungal agents and antimicrobials, 15 out of 32 (46.88%) of combinations between antifungal agents with non-antimicrobials, 16 out of 25 (64%) of combinations involving antifungal agents and natural compounds, and 3 out of 11 (22.27%) of combinations involving multiple natural compounds. Antagonistic interactions have been reported for 1 out of 32 (3.13%) and 8 out of 25 (32%) of combinations between antifungal drugs with non-antimicrobials and with natural compounds, respectively. Different drugs/compounds could potentiate the activity of antifungal drugs using this approach. However, despite the availability of this promising initial data, many more studies will be required to elucidate whether favourable interactions observed in vitro might translate into tangible clinical benefits. © 2021 Wiley-VCH GmbH
Related Docs
View other Related Docs
1. Drug Repurposing Against Candida Auris: A Systematic Review, Mycoses (2022)
2. Indifferent Effect of Nonsteroidal Anti-Inflammatory Drugs (Nsaids) Combined With Fluconazole Against Multidrug-Resistant Candida Auris, Current Medical Mycology (2019)
3. Candida Auris, an Emerging Fungal Pathogen, Journal of Mazandaran University of Medical Sciences (2019)
Experts (# of related papers)
View all Related Experts
Sadegh Khodavaisy (7)
kazem Ahmadikia (4)
Other Related Docs
4. Candida Auris: A New Emerging Fungal Monster, Archives of Clinical Infectious Diseases (2019)
5. A Review on Candida Auris, an Emerging Drug-Resistant Fungal Pathogen, Journal of Isfahan Medical School (2022)
6. Development of a High-Resolution Melt-Based Assay to Rapidly Detect the Azole-Resistant Candida Auris Isolates, Current Medical Mycology (2023)
7. Methods for Identification of Candida Auris, the Yeast of Global Public Health Concern: A Review, Journal de Mycologie Medicale (2019)
8. South Asian (Clade I) Candida Auris Meningitis in a Paediatric Patient in Iran With a Review of the Literature, Mycoses (2022)
9. Confirmation of Fifth Candida Auris Clade by Whole Genome Sequencing, Emerging Microbes and Infections (2022)
10. Clinical, Epidemiological, and Mycological Features of Patients With Candidemia: Experience in Two Tertiary Referral Centers in Iran, Current Medical Mycology (2022)
11. Species Distribution and Antifungal Susceptibility Profile of Candida Isolates From Blood and Other Normally Sterile Foci From Pediatric Icu Patients in Tehran, Iran, Medical Mycology (2020)
12. Antifungal Susceptibility Testing of Candida Species Isolated From the Immunocompromised Patients Admitted to Ten University Hospitals in Iran: Comparison of Colonizing and Infecting Isolates, BMC Infectious Diseases (2017)
13. Antifungal Susceptibility Profile of Candida Species and Uncommon Yeasts From Drug Abusers With Oral Candidiasis, BMC Oral Health (2024)
14. Enhancement of the Anti-Biofilm Activity of Gold Nanoparticles-Itraconazole Conjugates in Resistant Candida Glabrata, Recent Advances in Anti-Infective Drug Discovery (2021)
15. In Vitro Combination of Antifungal Drugs With Tacrolimus (Fk506) Holds Promise Against Clinical Candida Species, Including Candida Auris, Medical Mycology (2023)
16. Investigation of Erg11 Gene Expression Among Fluconazole-Resistant Candida Albicans: First Report From an Iranian Referral Paediatric Hospital, British Journal of Biomedical Science (2015)
17. Antifungal Activity of Capric Acid, Nystatin, and Fluconazole and Their in Vitro Interactions Against Candida Isolates From Neonatal Oral Thrush, Assay and Drug Development Technologies (2020)
18. Regulation of Erg3, Erg6, and Erg11 Genes in Antifungal-Resistant Isolates of Candida Parapsilosis, Iranian Biomedical Journal (2017)
19. Susceptibility Pattern of Caspofungin-Coated Gold Nanoparticles Against Clinically Important Candida Species, Advanced Pharmaceutical Bulletin (2021)
20. Antifungal Properties of Cathelicidin Ll-37: Current Knowledge and Future Research Directions, World Journal of Microbiology and Biotechnology (2024)